A Vaccine Built for Onea visual explainer Aug 19, 2026

Merck + Moderna · Phase 3 INTerpath-001 · August 19, 2026

A vaccine built
for one.

For the first time in cancer medicine, a therapy custom-built from a patient’s own tumor — intismeran autogene, an mRNA vaccine unlike any other — has passed the hardest test in drug development: a large randomized Phase 3 trial showing it helps keep high-risk melanoma from coming back after surgery.

0patients randomized
in 26 countries
0neoantigen targets,
chosen per patient
0injections, alongside
a year of KEYTRUDA
1stPhase 3 win ever for an
mRNA cancer therapy
Primary endpoint met — recurrence-free survival Key secondary met — distant metastasis-free survival Overall survival — still being measured
What actually happened
01

The announcement

What was actually announced

On the morning of August 19, 2026, Merck and Moderna issued a joint press release: the Phase 3 INTerpath-001 trial — the pivotal test of their personalized cancer vaccine — had met its main goal.1

The topline, in plain language

After surgery to remove high-risk melanoma, 1,137 patients worldwide were randomly assigned to one of two paths for about a year:

  • A
    KEYTRUDA + intismeran — the standard immunotherapy plus the custom mRNA vaccine
  • B
    KEYTRUDA + placebo — the standard immunotherapy alone (a placebo stood in for the vaccine)

At a pre-planned checkpoint called an , the group getting the vaccine did meaningfully better on both the trial was built to test:

primary endpoint · met
Patients stayed free of their cancer returning — or survived — longer.
key secondary · met
Patients went longer without melanoma showing up in distant organs — the spread that kills.

Merck called the improvements “statistically significant and clinically meaningful.” The safety profile matched earlier studies, with no new warning signs.1

02

The stakes

Why “gone” doesn’t always mean gone

is the most dangerous common skin cancer — and surgery is only the first battle.

Melanoma begins in melanocytes, the pigment-producing cells of the skin. It’s less common than other skin cancers but causes the large majority of skin-cancer deaths, and rates have been climbing for decades — driven largely by ultraviolet (UV) damage, which also loads melanoma cells with mutations.1,9

When caught early, it can usually be cut out. The trial’s patients had “completely resected” disease — surgeons removed every visible trace. But the fear isn’t what surgeons can see. It’s the microscopic cells they can’t.

“These patients may have no detectable cancer after surgery, but they can still have microscopic melanoma cells remaining somewhere in the body. Those cells can eventually begin growing again.”— Dr. Joan Levy, chief science officer, Melanoma Research Alliance7

Most recurrences surface within the first two years after surgery — and the majority come back as disease in distant organs, which is what makes melanoma lethal.1

0new melanoma cases diagnosed worldwide in 20221
0deaths from melanoma worldwide in 20229
0estimated new U.S. cases in 20261
0estimated U.S. deaths in 20261
Who this trial enrolled — stage IIB–IV, all surgically removed Stage IIB / IIC Still in the skin — but dangerous features thick or ulcerated tumor No detectable spread yet Stage III Reached nearby lymph nodes microscopic deposits in regional nodes Highest recurrence risk Stage IV Distant spread — but fully resected e.g. lung, liver, brain — removable A select group: surgery got it all Risk of the cancer coming back after surgery lower higher — stage III five-year recurrence ≈ 40–90%
scroll to explore →Fig. 1 — The patients in INTerpath-001 had stage IIB, IIC, III or IV cutaneous melanoma, completely removed by surgery, and none had received systemic drug therapy before.1,2 Staging described by Dr. Joan Levy.7

Today’s standard already helps — partway

For patients like these, doctors already offer “adjuvant” therapy — treatment given after surgery to kill leftovers before they regrow. The standard is (pembrolizumab), an immunotherapy that earned this role through two landmark trials: KEYNOTE-054 in stage III disease and KEYNOTE-716 in stage IIB/C.10

But “helps” isn’t “solves”

In KEYNOTE-054’s seven-year follow-up, pembrolizumab cut the recurrence rate meaningfully — yet about half of treated stage III patients still saw their cancer return or died within seven years (50% recurrence-free vs 36% on placebo).10 The open question for a decade: can we teach the immune system to do better than a general-purpose boost?

03

The idea

Two drugs, two jobs: release the brake, name the target

The combination works because each half covers the other’s weakness. Understanding that pairing is the key to understanding this whole story.

1KEYTRUDA releases the brake

T cell cancer cell PD-1 PD-L1 pembrolizumab blocks the dock T cell stays switched on

Cancers exploit a safety switch called : they wave a protein (PD-L1) that presses the T cell’s brake pedal and turns it off. KEYTRUDA is an antibody that jams that interaction — the brake can’t be pressed, so existing tumor-reactive T cells keep fighting.1 Checkpoint blockade earned its discoverers the 2018 Nobel Prize in medicine.

2Intismeran names the target

your cells neoantigen “flags” trained T cells stray cancer cell

But after surgery there may be too few T cells that recognize this tumor — the brake is released on an army that doesn’t know the enemy’s face. Intismeran is the missing briefing: an recipe encoding up to 34 of the tumor’s unique mutant proteins (). Injected into muscle, it teaches the immune system exactly what to hunt.1

“In simple terms, this therapy is like creating a custom-built ‘wanted poster’ for your immune system to hunt down your specific cancer.”

— Dr. Andrew Pecora, John Theurer Cancer Center, Hackensack7

One honest clarification: despite the “vaccine” shorthand, intismeran is not a shot that prevents melanoma in healthy people. It’s a treatment — a training course for the immune system of someone who has already had cancer, designed to keep it from returning.4

04

One patient, one drug

How a medicine is built for an audience of one

Every batch of intismeran is manufactured for a single person, from that person’s own tumor. Here’s the journey — roughly six weeks from biopsy to injection.8

  1. 1 · Biopsy + blood

    After surgery, a piece of the removed tumor and a blood sample go to the lab — the tumor’s DNA versus the patient’s healthy baseline.

  2. 2 · Read the fingerprint

    Sequencers compare tumor DNA to normal DNA and catalog the mutations — the mutational “fingerprint” unique to this cancer.

  3. 3 · Pick the 34

    A proprietary algorithm — built with Merck — scores the mutations and selects up to 34 neoantigens most likely to train a strong T-cell response.

  4. 4 · Write the mRNA

    One synthetic mRNA strand is designed to encode all 34 chosen targets — a genetic recipe that exists for this patient only.

  5. 5 · Manufacture + check

    The dose is synthesized, wrapped in protective lipid nanoparticles, filled, tested and released — at Moderna’s dedicated plant in Norwood, Massachusetts.

  6. 6 · Inject + repeat

    Shipped back to the clinic and injected into muscle — every 3 weeks, up to 9 doses, while KEYTRUDA is infused every 6 weeks for about a year.

Fig. 2 — The company’s stated turnaround is about six weeks from sample to injection — down from roughly 50–60 days in 2019; some independent estimates run two to four months.7,8
2016

Merck and Moderna began their cancer-vaccine collaboration; the first patient was dosed in a Phase 1 study in November 2017.8

1 of 1

Each manufactured batch treats exactly one patient. There is no warehouse of this drug — it exists because the patient does.

~6 wks

Company turnaround target per dose. Speed matters: microscopic disease can regrow while a bespoke medicine is being made.7

05

The evidence

The small trial that dared the big one

INTerpath-001 exists because a 157-patient Phase 2 study, KEYNOTE-942, kept refusing to let the signal die.3

From 2019 to 2021, researchers in the U.S. and Australia randomized 157 people with resected stage IIIB–IV melanoma: 107 received the vaccine (then called mRNA-4157) plus pembrolizumab; 50 got pembrolizumab alone.3

It was a real trial — but small and , and its first formal readout in 2023–24 was a statistical near-miss: a of 0.561 for recurrence with a p-value of 0.053, just past the conventional 0.05 line for “proof.”

Then the follow-up data kept arriving — and the benefit didn’t fade. With each successive analysis the confidence intervals tightened and crossed into nominal significance:

  • ~23 moRFS HR 0.561 · 18-mo recurrence-free 79% vs 62%3
  • ~3 yrsRFS HR 0.510 · DMFS HR 0.384 · 2.5-y recurrence-free 74.8% vs 55.6%5
  • ~5 yrsRFS HR 0.51 → 49% lower risk · DMFS HR 0.411 → 59% lower risk1

Safety trade-off seen in Phase 2: serious (grade ≥3) treatment-related side effects in 25% of combination patients vs 18% on pembrolizumab alone; most were mild-to-moderate.3

Hazard ratios over five years of follow-up

00.25 0.500.75 1.0 1.0 = no difference from KEYTRUDA alone ← bigger benefit RFS · 5-yr 0.51 RFS · 3-yr 0.510 RFS · primary 0.561 DMFS · 5-yr 0.411 DMFS · 3-yr 0.384
scroll to explore →Fig. 3 — Each dot is the estimated hazard ratio; whiskers are 95% confidence intervals. The amber point is the primary analysis whose interval grazed 1.0 (p=0.053) — the near-miss that Phase 3 was built to resolve. Data: Lancet 2024; ASCO 2024; ASCO 2026 via the companies.1,3,5
06

The trial

Inside INTerpath-001

The confirmatory test: seven times larger, double-blind, and run as a global Phase 3.2

1,137 patients enrolled stage IIB–IV, fully resected no prior systemic therapy 2 : 1 randomized Combination arm ≈ 2/3 of patients intismeran 1 mg injection every 3 wks · up to 9 doses + KEYTRUDA 400 mg IV every 6 wks · up to 9 cycles (~1 yr) Control arm ≈ 1/3 of patients placebo injection every 3 wks + KEYTRUDA 400 mg IV every 6 wks (~1 yr) Double-blind: patients, doctors and assessors didn’t know who got the real vaccine 165 sites · 26 countries · first enrolled July 2023 · follow-up continues to ~2030
scroll to explore →Fig. 4 — Trial design per the registry record (NCT05933577) and the companies’ release. Exact arm sizes weren’t disclosed; the 2:1 split means roughly two-thirds received the vaccine.1,2

Disclosed Aug 19

  • RFS — the primary endpoint — met at a pre-specified interim analysis
  • DMFS — a key secondary — met
  • Improvements “statistically significant and clinically meaningful”
  • Safety consistent with earlier studies; no new signals
  • Population: resected stage IIB–IV, no prior systemic therapy

Not yet disclosed

  • Hazard ratios, confidence intervals, p-values
  • How many recurrences actually happened in each arm
  • Median follow-up time and subgroup results
  • Overall survival — data still maturing
  • Detailed Phase 3 safety numbers

Independent coverage confirmed the gap: “the companies have not yet publicly disclosed the numerical Phase 3 hazard ratios, confidence intervals, absolute recurrence rates, subgroup results, or mature overall-survival data.”4

07

The context

How big a deal is this, really?

Genuinely historic — with honest asterisks. Here’s both.

01

First positive Phase 3 ever for an individualized neoantigen therapy — and for any mRNA-based cancer treatment.1

02

First Phase 3 to beat KEYTRUDA alone in adjuvant melanoma — it improved on the standard, not a placebo.1

03

Proof of a manufacturing paradigm: a medicine invented per-patient can succeed at Phase 3 scale, not just in boutique trials.

The road here was paved with failures

Cancer vaccines are a graveyard of good ideas. Decades of attempts — peptide vaccines, dendritic-cell vaccines, whole-tumor preparations — mostly failed to move the needle in randomized trials. The one therapeutic cancer vaccine ever FDA-approved, sipuleucel-T for prostate cancer (2010), extended survival by only about four months and never transformed care.

Two things changed: checkpoint inhibitors showed the immune system can control established cancer, and mRNA made it cheap and fast to encode a different recipe for every patient. The COVID-19 vaccines proved the platform could be manufactured at scale. Intismeran is where those two currents met.

How the world read it

The market’s reaction was violent: Moderna’s shares rose ~177% in one day (adding ~$45 billion in market value) and Merck hit a record high — moves driven by hope for a new category of medicine, not by the undisclosed data.6 Analyst projections of $3–5 billion in peak melanoma sales are speculation, not evidence. The measured expert view:

“A positive Phase 3 result is a major step, but it’s not yet standard treatment. The study is still ongoing, and the detailed, longer-term data will tell us just how big a difference it truly makes.”— Dr. Shirin Bajaj, dermatologist/Mohs surgeon7

Eight more trials are already running

The INTerpath program is testing intismeran across four cancer types — melanoma’s win is the first domino, not the whole row.1

TrialCancer & settingPhase~N
-001Melanoma · after surgery met endpoints31,137
-012Melanoma · first-line advanced2160
-002Lung (NSCLC) · after surgery3868
-009Lung · after chemo+Keytruda, surgery3680
-013Lung (squamous) · metastatic 1L2180
-014Lung · stage I after surgery3876
-004Kidney (RCC) · after surgery2272
-005Bladder (muscle-invasive) · post-op1/2230
-011Bladder (non-muscle-invasive)2308
scroll to explore →Fig. 5 — Plus the Phase 2b KEYNOTE-942 and a Phase 1 in pancreatic, gastric and perioperative lung cancers. Whether the vaccine works beyond melanoma is unknown — each row is still an open question.1
08

What happens next

The clock that’s still running

A topline success starts a clock, it doesn’t stop one. The trial continues — and several verdicts are still out.

  1. 2016
    Merck + Moderna partner on personalized cancer vaccines; first patient dosed 2017.8
  2. 2019–21
    KEYNOTE-942 enrolls 157 resected-melanoma patients.3
  3. Jul 2023
    INTerpath-001 begins — 165 sites, 26 countries.2
  4. Jun 2026
    Five-year Phase 2 data at ASCO: 49% lower recurrence risk, 59% lower distant-spread risk.1
  5. Aug 19, 2026
    Phase 3 meets RFS + DMFS. The announcement this page explains.1
  6. Next
    Full data at a medical meeting — hazard ratios, absolute benefits, subgroups, safety detail.1
  7. Then
    Regulatory filings — the companies say they’ll engage authorities; nothing is approved yet.
  8. ~2029–30
    Overall survival & completion — the answer to the only question that ultimately matters: does it help people live longer?2

The honest scorecard

Established

  • The combination beat KEYTRUDA alone on recurrence and on distant spread — in both a 157-patient Phase 2 (quantified) and a 1,137-patient Phase 3 (topline).1,3
  • Side effects in Phase 3 were consistent with prior studies — no new signals.1
  • A per-patient medicine can be manufactured and tested at global scale.

Still pending

  • How much it helps in Phase 3 — effect sizes unreleased.
  • Whether it extends life — overall survival not yet reported.1
  • Approval — filings planned, none granted; not standard care yet.7
  • Benefit in other cancers, cost, access, and real-world turnaround.7
09

Sources & method

Where every number came from

This explainer was built from primary sources — the trial registry, the companies’ release, and the peer-reviewed Phase 2 data — cross-checked against independent oncology and general news coverage.

  1. Merck & Moderna joint press release, “Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of RFS and DMFS,” Aug 19, 2026 — announcement, trial design, Phase 2 five-year figures, quotes, melanoma statistics. merck.com
  2. ClinicalTrials.gov NCT05933577 — registry record: enrollment, masking, sites, countries, endpoints, timeline. clinicaltrials.gov
  3. Weber JS et al., The Lancet (2024) — KEYNOTE-942 primary analysis: HR 0.561, p=0.053, 18-mo rates, safety. thelancet.com
  4. Independent analyses of the announcement — The ASCO Post (ascopost.com); Gilmore Health (gilmorehealth.com); Reuters (Aug 19–21, 2026): confirmation that Phase 3 effect sizes were not disclosed; expert and market context.
  5. KEYNOTE-942 updates — 3-year analysis (ASCO 2024, LBA9512; JCO) and Merck’s June 3, 2024 release; 5-year data via ASCO 2026 and the Aug 2026 release. doi.org/10.1200/JCO.2024.42.17_suppl.LBA9512
  6. Market coverage — Reuters; Business Insider; BioPharma Dive (Aug 19–20, 2026): MRNA +~177%, MRK record, analyst sales projections. Reported as market sentiment, not clinical evidence.
  7. Medical News Today expert panel (Aug 21, 2026) — Drs. Levy, Atkins, Pecora, Margolin, Annunziata, Bajaj, Gomolin: staging explanations, mechanism, “wanted poster” analogy, cautions. medicalnewstoday.com
  8. Manufacturing & history — Moderna, “One Medicine for One Patient”; BioSpace on bespoke-mRNA production: ~6-week turnaround, Norwood plant, 2016 partnership, 2017 first dose.
  9. Global melanoma burden — IARC/WHO (GLOBOCAN 2022): ~330,000 cases, ~60,000 deaths worldwide.
  10. Adjuvant pembrolizumab basis — KEYNOTE-054 (Lancet Oncology 2021; 7-yr analysis, EJC 2024) and KEYNOTE-716 (Lancet 2022): how KEYTRUDA became standard after surgery.

Read this before sharing

This is an independent educational explainer — not medical advice, not investment advice, and not affiliated with or endorsed by Merck or Moderna. Phase 2 figures quoted for KEYNOTE-942 are published; Phase 3 INTerpath-001 effect sizes had not been released as of this writing (September 13, 2026). If you or someone you love is making treatment decisions, talk to an oncologist — trial data describes populations, not your individual case.

More demos
Get started with Devin CLI